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SETD1A modulates cell cycle progression through
a miRNA network that regulates p53 target genes
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Expression of the p53-inducible antiproliferative gene BTG2 is suppressed in many cancers in
the absence of inactivating gene mutations, suggesting alternative mechanisms of silencing.
Using a shRNA screen targeting 43 histone lysine methyltransferases (KMTs), we show that
SETD1A suppresses BTG2 expression through its induction of several BTG2-targeting
miRNAs. This indirect but highly speciﬁc mechanism, by which a chromatin regulator that
mediates transcriptional activating marks can lead to the downregulation of a critical effector
gene, is shared with multiple genes in the p53 pathway. Through such miRNA-dependent
effects, SETD1A regulates cell cycle progression in vitro and modulates tumorigenesis in
mouse xenograft models. Together, these observations help explain the remarkably speciﬁc
genetic consequences associated with alterations in generic chromatin modulators in cancer.
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B
TG2, a p53-inducible gene, plays a critical role in
p53-mediated suppression of mouse and human ﬁbroblast
transformation induced by oncogenic-Ras1. BTG2 inhibits
cell cycle progression and its depletion enhances tumorigenesis in
mouse models. In human cancers, including breast and prostate
cancers, BTG2 expression is suppressed2. Despite its tumour-
suppressor effects, mutations in BTG2 have not been detected,
suggesting that epigenetic mechanisms could be involved in
modulating BTG2 expression in cells.
Chromatin-modifying enzymes are emerging as important
regulators of tumorigenesis, as well as promising cancer
therapeutic targets. Despite their broad effects on chromatin
structure, they also have striking target speciﬁcity, a paradox that
is poorly understood. Histone methylation, catalysed by lysine
methyltransferases (KMT), has been linked to both transcrip-
tional activation (H3K4, H3K36 and H3K79) and repression
(H3K9, H3K27 and H4K20)3. The Set1/COMPASS family of
H3K4 methyltransferases, ﬁrst identiﬁed in Saccharomyces
cerevisiae, consists of several members in humans and is
associated with transcriptional activation4. Although H3K4
methylation is associated with transcriptional activation, the
overall change in gene expression landscape within a cell may
depend on complex interplay between the target genes induced,
which may lead to secondary effects that repress as well as induce
gene expression.
Here we conducted an unbiased short hairpin RNA (shRNA)
screen against 43 KMTs to determine whether baseline expression
of BTG2 in proliferating cells is regulated by epigenetic
mechanisms. We identiﬁed SETD1A as a KMT whose knock-
down strongly induces activation of BTG2. This paradoxical
repressive effect of an activating chromatin regulator results from
its transcriptional activation of multiple microRNAs (miRNAs),
which themselves suppress the BTG2 transcript. This effect is
consistent with the roles of miRNAs in coordinating multiple
downstream targets that play important roles in cellular
differentiation, proliferation and signalling5,6. In addition to
targeting BTG2, SETD1A-induced miRNAs target additional
downstream effectors of p53, as well as cell cycle regulators. These
ﬁndings illustrate the exquisite target speciﬁcity exhibited by
chromatin-modifying enzymes, and the complex network
through which chromatin regulators inﬂuence genes involved in
tumorigenesis.
Results
Identiﬁcation of SETD1A as a regulator of BTG2 expression.
To investigate whether epigenetic silencing is involved in
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Figure 1 | BTG2 expression is regulated by SETD1A. (a) Knockdown of SETD1A speciﬁcally induces BTG2. A lentiviral shRNA screen against H3K4 KMTs
in MDA-MB-231 cells shows that SETD1A depletion speciﬁcally induces BTG2 expression compared with pLKO-infected control cells. Fold change in BTG2
and KMT expression after 72 h of viral infection is shown with controls set at 1. The dotted line marks twofold induction of BTG2 compared with control.
KMTs and BTG2 are shown as red and blue/green bars, respectively. (b) Total proteins isolated from control and SETD1A-depleted MDA-MB-231 cells were
analysed for H3K4Me1, H3K4Me2, H3K4Me3, total histone H3 and -actin protein expression. (c) SETD1A suppresses BTG2 in prostate and lung cancer
cells. SETD1A and BTG2 expression in SETD1A-depleted cells represents the average derived from cells individually infected with the two different
shSETD1A constructs (shSETD1A#1 and shSETD1A#2), with the shGFP-infected control set at 1. (d) Expression of lentivirally expressed SETD1A in
MCF10A cells decreases BTG2 expression (white bar). Fold expression of SETD1A in control and SETD1A-infected cells is shown (black bar). (e) WDR82,
a non-catalytic subunit of the SET1/COMPASS complex, regulates BTG2 expression. WDR82 and BTG2 expression in WDR82-depleted MDA-MB-231
cells represents the average derived from cells individually transfected with the two different siWDR82 sequences, with the siNT (non-targeting, NT)-
transfected control set at 1. Data are represented as mean±s.d. of the average of three experimental replicates. Asterisks indicate P values of Po0.05 for
a,c–e by Student’s t-test.
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suppressing BTG2 expression in proliferating cells, we measured
BTG2 induction in the human breast cancer cell line MDA-
MB-231, following infection with an arrayed lentiviral shRNA
library containing shRNAs against 43 KMTs. Four to ten
independent shRNA constructs were tested, targeting each KMT
implicated in chromatin marks, H3K4, H3K9, H3K27, H3K36,
H3K79 and H4K20 methylation, as well as unknown substrates
(Supplementary Fig. 1a). Baseline BTG2 mRNA is undetectable in
MDA-MB-231 cells, facilitating measurement of its induction 3
days after infection. Successful knockdown of KMT expression
(440%) with at least two shRNAs, compared with control pLKO
vector-infected cells, was observed for 32 of the 43 targeted KMTs
(Fig. 1a and Supplementary Fig. 1b). Among these, knockdown of
SETD1A by eight of nine shRNAs was unique in leading to a
2–4.5-fold increase in BTG2 mRNA (Fig. 1a). Knockdown of no
other KMT led to a signiﬁcant and robust increase or decrease in
BTG2 expression (Fig. 1a and Supplementary Fig. 1b). Depletion
of SETD1A, a KMT whose expression is increased in breast,
prostate and lung cancers7,8 (Supplementary Fig. 2a), did not alter
total H3K4Me1, H3K4Me2 and H3K4Me3 and histone H3 levels
in cells (Fig. 1b and Supplementary Fig. 8a). BTG2 mRNA
induction (up to 10-fold) on SETD1A depletion was observed in
multiple breast (n¼ 4), prostate (n¼ 2), lung (n¼ 2) and colon
(n¼ 6) cancer cell lines, and it was independent of the mutational
status of p53, a known regulator of BTG2 (Fig. 1c and
Supplementary Fig. 2b; Po0.05, Student’s t-test). In addition to
mRNA quantiﬁcation, SETD1A-mediated BTG2 regulation was
validated using western blot analysis (Supplementary Fig. 2c
and Supplementary Fig. 8b). Further, ectopic overexpression
of SETD1A in MCF10A breast epithelial cells, which express
BTG2 at baseline, led to reduced expression of the endogenous
transcript (Fig. 1d; Po0.05, Student’s t-test). Depletion of
WDR82, a non-catalytic subunit speciﬁc to the SET1/
COMPASS complexes (SETD1A and SETD1B) and not shared
by the MLL/COMPASS complexes4, also induced BTG2
expression (Fig. 1e). Consistent with these ﬁndings, analysis
of a large data set consisting prostate tumours9,10 showed a
signiﬁcant inverse correlation between BTG2 and SETD1A
mRNA expression in tumours, an effect that was most
pronounced in lower-grade prostate tumours (Gleason
score r6). No such correlation was present in normal prostate
tissue (Supplementary Fig. 3a); a similar negative correlation was
also observed in breast11 and lung12,13 cancers (Supplementary
Fig. 3b).
SETD1A suppresses BTG2 expression through a miRNA network.
Having identiﬁed a pronounced effect of a KMT chromatin
regulator on BTG2 expression, we ﬁrst analysed the
chromatin marks at the BTG2 promoter. Tiled chromatin
immunoprecipitation–quantitative PCR (ChIP–qPCR) across a
5-kb region spanning the BTG2 transcriptional start site
(Supplementary Fig. 4a) demonstrated peaks of H3K4Me1,
H3K4Me2 and H3K4Me3 marks in the proximity of the tran-
scription start site (Supplementary Fig. 4a–d). SETD1A depletion
led to a signiﬁcant decline in the H3K4Me3 peaks as well as
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Figure 2 | SETD1A regulates BTG2 through induction of miRNAs. (a) Regulation of BTG2 expression by SETD1A is mediated through miRNAs. SETD1A
regulates miRNA-32 and -590-5p, whose expression was analysed using qPCR in shGFP and shSETD1A-infected MDA-MB-231, DU145 and A549 cells.
Expression of miRNAs in controls was set at 1. Expression of the miRNAs in SETD1A-depleted cells represents the average derived from cells individually
infected with two shSETD1A constructs. (b) Suppression of miRNA-32 and -590-5p with Anti-miRs induces BTG2 expression. Expression of the two
miRNAs indicated was suppressed with Anti-miRs, and each miRNA (left) and BTG2 mRNA (right) was measured using qPCR. The level of each miRNA
and BTG2 in cells transfected with non-targeting (NT) sequences was set at 1. (c) Expression of miRNA-32 and -590-5p abrogates BTG2 induction in
SETD1A-depleted cells. BTG2 expression in shGFP-infected control cells transfected with NTsequences was set at 1. (d) miRNA-32 and -590-5p, target the
30-UTR of BTG2. A plasmid containing GFP linked to 30-UTR of BTG2 was co-transfected with the two miRNA sequences into 293Tcells, and the intensity of
GFP expression was monitored by ﬂuorescence-activated cell sorting. NTsequences were used as control and the intensity of GFP in this sample was set at
100%. (e) Deletion of the region harbouring binding sites for miRNA-32 and -590 from the 30-UTR of BTG2 abrogates miRNA-32- and -590-5p-mediated
suppression of the 30-UTR of BTG2. Data are represented as mean±s.d. of the average of three experimental replicates. Asterisks indicate P values of
Po0.05 for all ﬁgures by Student’s t-test. For the relevant ﬁgures, NT represents NT, and 590 indicates miRNA-590-5p.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9257 ARTICLE
NATURE COMMUNICATIONS | 6:8257 | DOI: 10.1038/ncomms9257 | www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
SETD1A occupancy within this area (Supplementary Fig. 4d,e;
Po0.05, Student’s t-test) suggesting that SETD1A maintains the
activating H3K4 methylation marks on the BTG2 promoter. As
control, depleting MLL did not affect H3K4 marks or MLL
occupancy on the BTG2 promoter, suggesting that BTG2 is a
speciﬁc target of SETD1A (Supplementary Fig. 4f,g). However,
the presence of activating chromatin marks on the BTG2
promoter would have suggested that SETD1A depletion should
result in decreased BTG2 expression, rather than the observed
BTG2 induction. To better understand this apparent paradox,
we investigated whether SETD1A might also induce negative
regulators of BTG2, namely miRNAs.
We screened for miRNAs differentially expressed in
shSETD1A or shGFP-infected MDA-MB-231 cells. SETD1A
knockdown using two independent shRNAs led to an upregula-
tion of 67 miRNAs (more than twofold) and suppression of
80 miRNAs (B60%; Supplementary Table 1). Three target
prediction algorithms, TargetScan14, miRanda15 and PicTar16,
identiﬁed the downregulation of ﬁve BTG2-targeting miRNAs,
miR-590-5p, miR-27a, miR-186, miR-20b and miR-32, in
SETD1A-depleted cells. We further validated and characterized
two BTG2-targeting miRNAs: miR-590-5p, which shows the
highest levels of suppression (B75%) in SETD1A-depleted cells,
and the previously identiﬁed BTG2-targeting miR-32 (ref. 17).
Depletion of SETD1A suppressed both miRNAs in multiple
cell lines (Fig. 2a and Supplementary Fig. 5a; Po0.05,
Student’s t-test). Suppressing the miRNAs with corresponding
anti-miRs increased BTG2 mRNA two- to fourfold (Fig. 2b
and Supplementary Fig. 5b; Po0.05, Student’s t-test), whereas
restoration of either miRNAs individually into SETD1A-depleted
cell lines abolished BTG2 induction (Fig. 2c and Supplementary
Fig. 5c; Po0.05, Student’s t-test). Expression of a green
ﬂuorescent protein (GFP) construct linked to the
30-untranslated repeat (UTR) of BTG2 demonstrated that
both miRNAs suppress GFP expression in cells (Fig. 2d).
Deletion of the region harbouring the two miRNA-32-binding
sites and the single miRNA-590-binding site from the 30-UTR of
BTG2 abrogated this effect (Fig. 2e and Supplementary Fig. 5d).
Thus, the repression of miRNA-32 and -590-5p expression by
SETD1A depletion may contribute to the increase in BTG2
mRNA levels.
Interestingly, expression of both miR-32 and -590-5p is
increased in breast cancer samples compared with normal tissue
(P¼ 1.4e 31 for miR-32, P¼ 6.18e 09 for miR-590-5p,
Student’s t-test; Supplementary Fig. 5e), and an inverse
correlation is observed between BTG2 expression and
miRNA-32 and -590-5p, supporting the relevance of these
ﬁndings in clinical specimens (cor¼  0.244, P¼ 1.33e 11 for
BTG2/miR-32; cor¼  0.461, P¼ 1.32e 40 for BTG2/miR-
590-5p, Pearson’s correlation; Supplementary Fig. 5f). Together,
these results suggest that SETD1A-induced miRNAs suppress
BTG2 expression.
SETD1A regulates the promoters of BTG2-targeting miRNAs.
We then determined whether SETD1A directly regulates the
expression of BTG2-targeting miRNAs. miR-32 resides within
intron 12 of the host gene TMEM245, whose promoter isB90 kb
away from the miRNA (Supplementary Fig. 6a, green oval).
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Figure 3 | SETD1A regulates the promoters of miR-32 and miR-590-5p. (a) H3K4Me1, H3K4Me2 and H3K4Me3 marks on the promoter region of
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promoter do not change on SETD1A knockdown (Fig. 3a). Thus,
the suppression of miR-32 is not due to TMEM245 host gene
regulation. The UCSC genome database revealed a proximal
H3K4Me3 peak B4 kb away from miR-32 (Supplementary
Fig. 6a, red oval). ChIP analysis of this region demonstrates
that both SETD1A binding and H3K4Me3 are signiﬁcantly
reduced on SETD1A depletion (Fig. 3b; Po0.05, Student’s t-test).
We similarly evaluated miR-590, which localizes within the
host gene EIF4H, whose promoter is B15 kb upstream of the
miRNA (Supplementary Fig. 6b, green oval). Again, H3K4
methylation of the EIF4H promoter does not change on SETD1A
knockdown (Fig. 3c). Analysis of the region coinciding with the
miR-590 promoter previously described18 (Supplementary
Fig. 6b, red oval) demonstrates a signiﬁcant decrease in both
SETD1A binding and H3K4Me3 on SETD1A knockdown
(Fig. 3d; Po0.05, Student’s t-test). These results reveal that
BTG2-targeting miRNAs, miR-32 and miR-590, are both direct
targets of SETD1A and that they are induced independently of
their host transcripts by this chromatin regulator.
SETD1A-induced miRNAs are enriched for p53 target genes.
The effect of SETD1A on BTG2 expression may illustrate a
broader miRNA network by which this chromatin regulator
modulates genes involved in tumorigenesis. To evaluate the full
effect of SETD1A-induced miRNA targets, we identiﬁed
microRNA–mRNA interactions among all genes and miRNAs
differentially expressed in SETD1A-depleted MDA-MB-231 cells
using TargetScan, miRanda and PicTar14–16. Only those
identiﬁed by all three algorithms were selected to form a
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high-conﬁdence set of consensus microRNA targets. Of the 897
genes induced in SETD1A knockdown MDA-MB-231 cells, only
185 (20%) genes were miRNA targets (Fig. 4a and Supplementary
Table 2). Gene set enrichment analysis (GSEA) of these 185 genes
identiﬁed 100 gene signatures (Po7.06e 07, false discovery rate
(FDR) q-value (FDR) o4.50e 05, hypergeometric test; Fig. 4b
and Supplementary Table 3), with enrichment for genes induced
by p53 being the top hit (P¼ 1.6e 24, FDR¼ 1.04e 20, hyper-
geometric test19). Additional pathways signiﬁcantly enriched
were TP63 (P¼ 2.32e 22, FDR¼ 7.39e 19, hypergeometric
test19) and ESR1 (P¼ 1.26e 19, FDR¼ 2.68e 16, hypergeo-
metric test20) targets (Fig. 4b and Supplementary Table 3).
Comparison of these 185 miRNA targets induced in SETD1A-
depleted MDA-MB-231 cells against the set of genes comparably
induced in SETD1A-depleted A549 cells identiﬁed 31 consensus
genes (Fig. 4c,d). The 31 common SETD1A-regulated genes, thus
identiﬁed, were each found to be targeted by —one to ﬁve
SETD1A-induced miRNAs (Fig. 4d and Supplementary Table 4).
BTG2 is one of three genes (BTG2, ProSAPiP1 and TP53INP1)
targeted by the highest number of SETD1A-regulated miRNAs
(Supplementary Table 4). GSEA of the 31 genes also showed
signiﬁcant enrichment for canonical p53 downstream pathway
genes (P¼ 2.23e 6, FDR¼ 2.95e 3, Benjamini–Hochberg
method). Among the downstream components most signiﬁcantly
enriched, and independently conﬁrmed in multiple cell lines
using qPCR, are ARID3A, SESN1 and TP53INP1 (Fig. 4e).
Additional computational analyses (Gene, Disease Features
Ontology-based Overview System) showed that 21 of the 31
genes common between MDA-MB-231 and A549 cells (targeted
by 24 SETD1A-induced miRNAs) were signiﬁcantly related
to the p53 pathway, neoplasms and cell cycle regulation
(Supplementary Fig. 7a); StarBase enrichment analysis21,22 of
these 24 SETD1A-induced miRNAs shows that they are
signiﬁcantly enriched for components associated with negative
regulation of cell proliferation, and p53 and cancer-associated
pathways (Supplementary Fig. 7b). Taken all together, these
results show that SETD1A-regulated miRNAs target multiple
genes involved in cell cycle regulation, and p53 downstream
pathways, including BTG2.
SETD1A depletion inhibits the cell cycle and tumour growth.
To determine the functional consequence of SETD1A, we
analysed cell cycle distribution in SETD1A-depleted cells.
Consistent with the cell cycle-regulatory effects of BTG2 (ref. 2),
depletion of SETD1A modulates cell cycle progression in cancer
cells. In MDA-MB-231 as well as in A549 lung cancer cells and in
DU145 prostate cancer cells, SETD1A depletion increased the G1
fraction (Fig. 5a; Po0.001, Student’s t-test). A similar increase
in the G1 fraction was also observed in WDR82-depleted
MDA-MB-231 cells (Fig. 5b). The increase in G1 induced by
SETD1A knockdown was partially reversed using siRNA-
mediated inhibition of BTG2 (Fig. 5c; Po0.005, Student’s t-test).
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Consistent with this effect, ectopic expression of miR-32 and
-590-5p mimics reduced the G1 fraction in SETD1A knockdown
cells (Fig. 5d; Po0.005, Student’s t-test). The effect of SETD1A
on cell proliferation was even more striking in vivo, where
SETD1A knockdown abrogated tumorigenesis of DU145 and
MDA-MB-231 cells (Fig. 6a–c; Po0.05, Student’s t-test).
Discussion
SETD1A-mediated regulation of BTG2 reveals a new dimension
in the complex regulatory pathways mediated by chromatin-
modifying enzymes. Although SETD1A regulates H3K4Me3
methylation of the BTG2 promoter, suggesting direct transcrip-
tional regulation of BTG2, it concurrently induces the expression
of several BTG2-targeting miRNAs. The ultimate consequence of
these opposing signals is the suppression of BTG2 expression,
reﬂecting the dominance of the miRNA-mediated effects.
Analysis of SETD1A-regulated miRNA/mRNA targets across
multiple cell lines shows that SETD1A-induced miRNA network
broadly suppresses the expression of p53 downstream targets and
cell cycle-regulatory genes in addition to BTG2. Of note, the
suppression of p53 downstream targets, ARID3A, SESN1,
TP53INP1 and BTG2, by SETD1A-induced miRNAs is indepen-
dent of the cellular p53 status. These ﬁndings identify a subset of
p53 target genes speciﬁcally induced by a chromatin modiﬁer
through a p53-independent regulatory mechanism, and
illustrate the exquisite speciﬁcity and complexity involved in
SETD1A-regulated gene expression.
Consistent with the induction of the p53 downstream targets,
BTG2, TP53INP1 and SESN1, all of which have tumour-
suppressor functions on their own2,23,24, SETD1A depletion
suppresses tumour growth in vivo. This establishes a new
functional role of SETD1A, which has previously been
identiﬁed as developmentally required for gastrulation, but
dispensable for mouse embryo implantation25. SETD1A is
responsible for maintenance of the majority of H3K4
methylation in embryonic stem cells. Our data, however,
demonstrate that SETD1A is not required for overall
maintenance of H3K4 methylation in tumour cells (Fig. 1b),
suggesting that SETD1A activity is dependent on the cellular
context. Protein–protein interactions deﬁning context-dependent
H3K4 trimethylation by Set1/COMPASS has been reported in
yeast26. Nonetheless, depletion of SETD1A in both tumour cells
and embryonic stem cells interferes with cell cycle progression by
increasing G1 (ref. 25). Whether SETD1A-mediated cell cycle
regulation in embryonic stem cells involves miRNA intermediates
remains to be determined.
In conclusion, the regulation of BTG2 by SETD1A serves
as a model to illustrate (1) the exquisite target speciﬁcity
exhibited by histone lysine methyltransferases, (2) a miRNA
network-mediated mechanism through which SETD1A, a
positive chromatin regulator of transcription, suppresses the
expression of several genes involved in cell cycle regulation and
the p53 pathway and (3) a new role for SETD1A in regulating
tumour growth. Given that the misregulation of H3K4 methyla-
tion resulting from MLL fusion proteins, mutant MLL3 and
MLL4 proteins, and aberrant demethylase activity has been
implicated in cancer progression27–29, our observations linking
the H3K4 regulator SETD1A in tumorigenesis supports the
importance of this chromatin modiﬁer and the potential
application of small molecules targeting the enzymatic activity
of KMTs in cancer.
Methods
Cell culture. Human breast, prostate and lung cancer cell lines MDA-MB-231,
MDA-MB-468, MCF7, BT549, DU145, LNCaP, A549 and H1299 were grown in
Dulbeccco’s modiﬁed medium. Human colon cancer cell lines HCT8, HCT116,
H630, DLD1, SW620 and HT29 were grown in RPMI 1640 medium. Both growth
media were supplemented with 10% fetal bovine serum and penicillin/streptomycin
(Pen/Strep). The non-tumorigenic MCF10A cells were cultured in DMEM/F12
medium with 5% horse serum, epidermal growth factor, Hydrocortizole, Cholera
Toxin, Insulin and Pen/Strep. All cell lines were purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines were
maintained in 5% CO2 at 37 C.
Screening for KMTs that modulate BTG2 expression. Lentiviral shRNA
constructs were obtained from the RNAi Consortium shRNA Library at the
Broad Institute. Conditioned medium containing infective lentiviral particles was
generated by co-transfecting 3 mg of lentiviral vector (plko1), 3 mg of pCMV d8.91
and 1 mg pHCMV-G into 1 106 293T human embryonic kidney cells using
FuGENE 6 transfection reagent (Roche Applied Science). Supernatants were
collected 48 h after transfection and were ﬁltered through a 0.45-mM membrane
(Millipore). Cells were infected using 8 mgml 1 polybrene and selected with
2 mgml 1 puromycin. RNA was isolated 72 h after infection and analysed using
qPCR for expression of BTG2 and each histone lysine methyltransferase. The
primer sequences used to analyse expression using qPCR are provided in
Supplementary Table 6.
Chromatin immunoprecipitation assay. SETD1A binding and H3K4 methylation
of BTG2, TMEM245, EIF4H, miR-32 and -590 were analysed using ChIP. The
genomic regions to be analysed were chosen on the basis of the H3K4Me3 proﬁles
obtained from the UCSC data. Cells were grown to 80% conﬂuence, crosslinked
with 1% formaldehyde for 15min at 37 C and quenched with formaldehyde
containing 125mM glycine. After washing twice with cold PBS, cells were collected
into 1ml of lysis buffer (5mM PIPES, 85mM KCl and 0.5% NP-40, Protease
Inhibitors). Nuclei were collected and incubated in nuclear lysis buffer (50mM Tris
(pH 8.0), 10mM EDTA (pH 8.0), 0.2% EDTA, Protease Inhibitors). The
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Figure 6 | SETD1A regulates tumorigenesis. (a) DU145 cells infected with
shGFP- and shSETD1A lentiviruses were inoculated subcutaneously into
immunocompromised mice. Fold change in tumour volume and the number
of animals in each group are shown. The volume of SETD1A-depleted
tumours represents the average derived from cells individually infected with
the two different shSETD1A constructs. Data are represented as mean±s.d.
of the average of each group. Asterisks indicate P values of Po0.05 by
Student’s t-test. (b) Luciferase expressing MDA-MB-231 cells infected with
shGFP- and shSETD1A lentiviruses were inoculated into the mammary fat
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animals in each group are shown. Data are represented as mean±s.d. of
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crosslinked chromatin was sonicated into DNA fragments of B300–500 bp in
length. Protein G beads were ﬁrst incubated on a rotator at 4 C for 6 h with 4 mg
each of the following antibodies against Histone H3 (Abcam, ab1791), Histone H3
monomethyl K4 (Abcam, ab8895), Histone H3 dimethyl K4 (Abcam, ab11946),
Histone H3 trimethyl K4 (Abcam, ab8580), SETD1A (BETHYL, A300–289A),
MLL (BETHYL, A300–374A) and control IgG (Cell Signaling, 2729S). Chromatin
solution (100 mg) was incubated with protein G magnetic beads conjugated with
antibodies overnight on a rotator at 4 C. After six washes, the beads were eluted
with elution buffer (50mM NaHCO3, 140mM NaCl, 1% SDS). Following both
RNaseA and proteinase K treatments, and reverse crosslinking, DNA was puriﬁed
with the PCR clean-up kit (Qiagen) and analysed with qPCR using primers against
the relevant targets listed in Supplementary Table 5.
Western blot analysis. The antibodies used for western blot analysis were rabbit
anti-SET1 polyclonal antibody (1:1,000, BETHYL, A300–289A), rabbit anti-BTG2
polyclonal antibody (1:2,000, GenWay Biotech, GWB-D54FE7), rabbit anti-His-
tone H3 antibody (1:1,000, Abcam, ab1791), rabbit anti-Histone H3 monomethyl
K4 antibody (1:500, Abcam, ab8895), Goat anti-Histone H3 dimethyl K4 antibody
(1:1,000, Abcam, ab11946), rabbit anti-Histone H3 trimethyl K4 antibody (1:1,000,
Abcam, ab8580) and mouse anti-Actin monoclonal antibody (1:5,000, BD
Bioscience, 612656). Cells were lysed in RIPA buffer (20mM Tris, pH 8.0, 150mM
NaCl, 10mM NaF, 0.1% SDS, 1% Nonidet P-40 and 1 protease inhibitor mixture
(Roche)), proteins were separated on a 4–15% polyacrylamide gradient–SDS gel
(Bio-Rad), transferred on polyvinylidene diﬂuoride membranes (Millipore) and
blocked in TBST (Tris-buffered saline and Tween 20; 25mM Tris, pH 7.4, 136mM
NaCl, 5mM KCl and 0.1% Tween) containing 5% milk. The antibodies were used
at each dilution, as described above, in 1% milk/TBST before use. Blots were
incubated with the primary antibodies for 2 h at room temperature. Blots were
washed (three times) with 1% milk/TBST and were incubated with the appropriate
horseradish peroxidase-conjugated antibodies. Bound antibodies were detected
with enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech).
Validation of SETD1A-regulated miRNAs. Brieﬂy, RNA isolated from shGFP-
and shSETD1A (shSETD1A#1 and shSETD1A#2)-infected MDA-MB-231 cells,
3 days after infection, was assayed with an A & B card consisting of probes against
a total of 756 miRNAs. The effect of SETD1A knockdown on miRNA expression
was calculated as the ratio of miRNA expression in shSETD1A-MDA-MB-231
and shGFP-MDA-MB-231 cells. An arbitrary threshold of 60% suppression and
twofold increase in expression were used to determine the miRNA population
that was regulated by SETD1A.
For further evaluation of selected targets, total RNA including miRNA was
isolated from cells using the mirVana miRNA Isolation Kit (Ambion). miRNAs
were detected using a two-step qRT–PCR, with the ﬁrst step being reverse
transcription (RT) of cDNA and the second step being real-time qPCR. All
reagents were supplied by Applied Biosystems. The RT reaction was performed in
15ml volume, containing 1.5 ml Taqman RT Buffer (10 ), 0.15 ml 100mM dNTPs
(100mM), 1.0 ml Reverse Transcriptase, 0.19 ml RNase inhibitor (20U ml 1), 3.0 ml
speciﬁc miRNA primer, 100 ng total RNA and nuclease-free water. Real-time qPCR
was performed in 20ml reaction volume using the standard protocols on an
Applied Biosystems 7900HT System. Brieﬂy, 2.5 ml of cDNA was mixed with 10 ml
TaqMan universal PCR master mix (2 ), 1.0 ml TaqMan miRNA assay and 6.5 ml
nuclease-free water. The reaction conditions were the same as above for real-time
PCR in array experiments. For each RNA sample, the target miRNA and RNU48
reactions were run in triplicate.
Mimics of miR-32 and -590-5p or control (50 nM) were transfected into cells
using the Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s
protocol. Anti-miRs against miR-32 and -590-5p mercury LNA or control (50 nM)
were similarly introduced into cells. The sequences of mimics and the anti-miRs
are given below.
miRIDIAN microRNA Mimics
hsa-miR-32-5p: 50-UAUUGCACAUUACUAAGUUGCA-30
hsa-miR-590-5p: 50-GAGCUUAUUCAUAAAAGUGCAG-30
Negative control: 50-UUGUACUACACAAAAGUACUG-30
miRCURY LNA inhibitor
hsa-miR-32-5p: 50-CAACTTAGTAATGTGCAAT-30
hsa-miR-590-5p: 50-CTGCACTTTTATGAATAAGCT-30
Negative control: 50-AGAGCTCCCTTCAATCCAAA-30
30-UTR plasmid reporter assay. pLenti-UTR-GFP plasmid, in which the 30-UTR
of BTG2 is inserted as the 30-UTR of GFP, was purchased from Applied Biological
Materials Inc. The 30-UTR of BTG2 lacking the binding sites for miR-32 and
-590-5p was derived from this plasmid using the QuickChange Lightning
Site-Directed Mutagenesis Kit (Agilent Technologies) according to the
manufacturer’s protocol. 293T human embryonic kidney cells were transfected
with both the wild-type and the miR-binding site-deleted pLenti-UTR plasmids
using X-tremeGENE HP DNA transfection reagent (Roche Applied Science).
Cells were transfected with miRNAs (miR-32, miR-590-5p or control) using
Lipofectamine RNAiMAX, 48 h after transfection, with pLenti-UTR-GFP and
were analysed with MACS Flow Cytometry (Miltenyl Biotec) for the mean
ﬂuorescent intensity 72 h after transfection of the miR.
RNA interference assay. siBTG2 sequence (50-CAGAGCACUACAAACACCA
CUGGUU-30), siWDR82#1 sequence (50-UCUCAUCUGUAGUUUCCAATT-30),
siWDR82#2 sequence (50-GAUCCAGAAGGGUUAAUUUTT-30) or control
(50 nM) were transfected into cells using the Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s protocol.
Cell cycle analysis. Cells were harvested, washed twice in PBS, resuspended in
0.1% saponin/PBS (Sigma) containing 10 mgml 1 RNase (Sigma) and 50 mgml 1
propidium iodide (Sigma) and incubated for 30min at 37 C. Samples were
analysed with ﬂow cytometry using the FACScalibur and CellQuest software
(Becton Dickinson).
In vivo tumorigenesis assay. DU145 cells (1 106) infected with shGFP and
shSETD1A lentiviruses (in 100 ml of 1:1 PBS and matrigel (BD Biosciences))
were separately inoculated subcutaneously into the ﬂanks on either side of 6- to
8-week-old male athymic nude mice (n¼ 3 for control; n¼ 6 for experimental
group). Tumours were measured every week and tumour volume was calculated as
lengthwidth2 0.52.
For MDA-MB-231 xenografts, 6-week-old female athymic nude mice (n¼ 6 for
control group, n¼ 10 for experimental group) were anaesthetized with isoﬂuorane,
and luciferase-tagged tumour cells (1 106) infected with shGFP and shSETD1A
lentiviruses (1 106) in 100 ml of 1:1 PBS and Matrigel (BD) were injected into the
fourth right mammary fat pad. Tumour-derived signals were monitored by in vivo
live imaging using IVIS Lumina II (PerkinElmer). D-Luciferon substrate
(PerkinElmer) was injected intraperitoneally at 150 ml per animal; mice were
anaesthetized after 5min; and bioluminescent images were taken.
All mice were cared for and experiments were performed under the AAALAS
guidelines using protocols approved by the institutional review board and the
institutional animal care and use committee of the Massachusetts General Hospital.
Arrayed gene expression analysis. RNA expression in SETD1A-depleted
A549 and MDA-MB-231 cells was analysed using the Human Gene Expression
12 135K Arrays (GPL17425, Roche Nimblegen). Brieﬂy, RNA was extracted
from A549 and MDA-MB-231 cells infected with shGFP or two independent
shSETD1A constructs (shSETD1A#1 and shSETD1A#2) using the RNeasy Mini kit
(Qiagen). cDNA synthesis was performed using the Roche cDNA synthesis system
(11 117 831 001). cDNA was hybridized to the Human Gene Expression
12 135K Arrays in duplicate according to the manufacturer’s protocol. The
microarrays were scanned on Nimblegen MS200 at 2 mm resolution. Scans were
converted to robust microarray average (RMA)-normalized expression values using
the Roche NimbleScan 2.6 software.
The list of upregulated genes common to MDA-MB-231 cells infected with
shSETD1A#1 and shSETD1A#2 was compiled. The 897 genes induced in
SETD1A-depleted cells thus identiﬁed were analysed against the 80 miRNAs
commonly suppressed in MDA-MB-231 cells infected with shSETD1A#1 and
shSETD1A#2. The 185 miRNA–mRNA interactions predicted by the three miRNA
target predictor programmes, TargetScan, miRanda and PicTar, were then
compared with the list of common genes upregulated in A549 cells infected with
shSETD1A#1 and SETD1A#2. This analysis identiﬁed 31 genes to be common
targets of SETD1A-regulated miRNAs. These 185 and 31 genes were then subjected
to pathway enrichment analysis (GSEA). The gene set enrichment hypergeometric
tests between the 185 miRNA targets and the curated gene lists (C2) of MSigDB
were accomplished using the investigate gene sets tool (http://www.broadinstitute.
org/gsea/msigdb/annotate.jsp; top 100 gene sets; FDR¼ 0.05). When noted, GSEA
was performed by the Broad Institute (Cambridge, MA, USA). P values were
generated using hypergeometric GSEA applied to the each subset of Broad’s
MSigDB gene set database. The Benjamini–Hochberg method was used to compute
FDR q-values from the P values.
Oncomine microarray data sets. Oncomine data sets were analysed for
differences in SETD1A mRNA between cancer and normal tissues (gene rank top
20%; P valueo0.005, Student’s t-test). Representative box plot from Oncomine
(www.oncomine.org) is shown to illustrate the difference in SETD1A mRNA levels.
All data are log-transformed and median-centred, and the 25th–75th percentiles
are indicated by the closed box.
Statistical analysis. Statistical analysis was performed with a two-tailed Student’s
t-test or as described in each method by the Broad Institute. The differences
between the means were considered to be statistically signiﬁcant at Po0.05.
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